Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06512168 · ClinicalTrials.gov registry record · NA

Measuring Aided Language Development

A NA study of Cerebral Palsy and Down Syndrome, sponsored by University of Central Florida.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT06512168 is a NA study of Cerebral Palsy and Down Syndrome that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 60 participants, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06512168, a NA study of Cerebral Palsy and Down Syndrome, is actively recruiting participants, sponsored by University of Central Florida.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The focus of the current study is to systematically investigate the psychometric properties of a range of aided language measures, which are based on the Graphic Symbol Utterance and Sentence Development Framework (Binger \& Kent-Walsh).

Interventions

  • BEHAVIORAL AAC Generative Language Intervention

Study Locations (1)

Florida

  • University of Central Florida - Innovative Center - Orlando

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-04-01
Est. Completion 2028-03-31
Phase NA

Sponsor

University of Central Florida

91 total trials

What the Registry Record Tells You About NCT06512168

The ClinicalTrials.gov registry entry for NCT06512168 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (74% lower). The listed sponsor is University of Central Florida, which has 91 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Cerebral Palsy appearing as the primary indexed condition, and to 1 intervention - of which AAC Generative Language Intervention is the first listed.

NCT06512168 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06512168 about?

NCT06512168 is a clinical study titled "Measuring Aided Language Development". The focus of the current study is to systematically investigate the psychometric properties of a range of aided language measures, which are based on the Graphic Symbol Utterance and Sentence Development Framework (Binger \& Kent-Walsh).

What is the current status of trial NCT06512168?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-04-01. Estimated completion is 2028-03-31.

What conditions does trial NCT06512168 study?

This clinical trial studies the following conditions: Cerebral Palsy, Down Syndrome, Speech Sound Disorder, Apraxia of Speech, Speech and Language Disorder.

What interventions are being tested in trial NCT06512168?

The interventions under investigation include: AAC Generative Language Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT06512168?

This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06512168 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebral Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.